Literature DB >> 32299780

Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19.

Tonino Bombardini1, Eugenio Picano2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32299780      PMCID： PMC7118531          DOI： 10.1016/j.cjca.2020.03.026

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


× No keyword cloud information.
  2 in total

1.  ACE and ACE2: a tale of two enzymes.

Authors:  Lawrence S Zisman
Journal:  Eur Heart J       Date:  2005-01-25       Impact factor: 29.983

2.  Angiotensin-converting enzyme 2 protects from severe acute lung failure.

Authors:  Yumiko Imai; Keiji Kuba; Shuan Rao; Yi Huan; Feng Guo; Bin Guan; Peng Yang; Renu Sarao; Teiji Wada; Howard Leong-Poi; Michael A Crackower; Akiyoshi Fukamizu; Chi-Chung Hui; Lutz Hein; Stefan Uhlig; Arthur S Slutsky; Chengyu Jiang; Josef M Penninger
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962
  2 in total
  13 in total

1.  What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?

Authors:  Thadathilankal-Jess John; Kiran John
Journal:  Can J Cardiol       Date:  2020-04-08       Impact factor: 5.223

2.  Silent hypoxia: a frequently overlooked clinical entity in patients with COVID-19.

Authors:  Atanu Chandra; Uddalak Chakraborty; Jyotirmoy Pal; Parthasarathi Karmakar
Journal:  BMJ Case Rep       Date:  2020-09-07

3.  A Focus on COVID-19: Fast and Accurate Information to Guide Management for Pandemic-Related Issues in Cardiac Patients.

Authors:  Stanley Nattel; Michelle Graham; Andrew Krahn
Journal:  Can J Cardiol       Date:  2020-04-25       Impact factor: 5.223

Review 4.  The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.

Authors:  Iqrar Ahmad; Rahul Pawara; Sanjay Surana; Harun Patel
Journal:  Top Curr Chem (Cham)       Date:  2021-10-08

Review 5.  COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development.

Authors:  Joowon Yim; Hee Hyun Lim; Youngjoo Kwon
Journal:  Arch Pharm Res       Date:  2021-05-28       Impact factor: 6.010

Review 6.  Perspective: improving vitamin D status in the management of COVID-19.

Authors:  Maryam Ebadi; Aldo J Montano-Loza
Journal:  Eur J Clin Nutr       Date:  2020-05-12       Impact factor: 4.016

Review 7.  Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity.

Authors:  Joseph Mercola; William B Grant; Carol L Wagner
Journal:  Nutrients       Date:  2020-10-31       Impact factor: 5.717

8.  Is vitamin D deficiency a risk factor for COVID-19 in children?

Authors:  Kamil Yılmaz; Velat Şen
Journal:  Pediatr Pulmonol       Date:  2020-10-13

Review 9.  A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system.

Authors:  Anastasia Williams; Heather Branscome; Pooja Khatkar; Gifty A Mensah; Sarah Al Sharif; Daniel O Pinto; Catherine DeMarino; Fatah Kashanchi
Journal:  J Neurovirol       Date:  2021-09-28       Impact factor: 2.643

Review 10.  Causal Links between Hypovitaminosis D and Dysregulation of the T Cell Connection of Immunity Associated with Obesity and Concomitant Pathologies.

Authors:  Natalia Todosenko; Maria Vulf; Kristina Yurova; Olga Khaziakhmatova; Larisa Mikhailova; Larisa Litvinova
Journal:  Biomedicines       Date:  2021-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.